Bristol Myers celebrates a big win with FDA approval of $13B cardio drug mavacamten
After getting hit with an FDA delay back in November, Bristol Myers Squibb is finally celebrating a win for mavacamten, the centerpiece of the company’s $13 billion MyoKardia buyout back in 2020.
Regulators approved mavacamten on Thursday to treat symptomatic obstructive hypertrophic cardiomyopathy, or oHCM: a condition in which the muscular wall between the two bottom chambers of the heart becomes thicker than normal, blocking blood flow out of the heart.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,100+ biopharma pros reading Endpoints daily — and it's free.